XBIT
XBiotech Inc is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases.
XBiotech Inc. (XBIT) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (C). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B+ (3.5) | C+ (2.5) | C (2.5) | C (2.5) | C+ (2.6) | C+ (2.7) |
| 2026-11-08 | B+ (3.6) | C+ (2.5) | C (2.4) | C+ (2.6) | C+ (2.6) | C+ (2.7) |
| 2026-11-01 | B+ (3.5) | C+ (2.5) | C (2.4) | C (2.4) | C+ (2.7) | C+ (2.7) |
| 2026-10-25 | B+ (3.5) | C+ (2.5) | C (2.4) | C (2.2) | C+ (2.6) | C+ (2.6) |
| 2026-10-18 | B (3.5) | C+ (2.5) | C (2.4) | C (2.4) | C+ (2.6) | C+ (2.7) |